When the initial visual-acuity letter score was @ to @ ( equivalent to approximately @/@ to @/@ ) ( @ % of participants ) , the mean improvement was @ with aflibercept , @ with bevacizumab , and @ with ranibizumab ( P > @ for each pairwise comparison ) .